EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual Targeting of HIF-1α and DLL4 by Isoxanthohumol Potentiates Immune Checkpoint Blockade

Doyoung Kim, Jihye You iD, So Hee Bae iD, Ji-Hak Jeong, Jong Hwa Jung iD, Jeong Ah Kim iD, You Mie Lee iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Doyoung Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vessel-Organ Interaction Research Center, VOICE (MRC), College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea. Hauptthemen laut MEDLINE: Hypoxia-Inducible Factor 1, alpha Subunit, Xanthones, Immune Checkpoint Inhibitors, Carcinoma, Lewis Lung. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government of the Republic of Korea, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor angiogenesis is a critical driver of cancer progression; however, current anti-angiogenic therapies remain limited by resistance and toxicity. Hypoxia within the tumor microenvironment induces hypoxia-inducible factor-1α (HIF-1α), which promotes aberrant angiogenesis by upregulating vascular endothelial growth factor (VEGF) and, subsequently, delta-like ligand 4 (DLL4) in endothelial cells. A systematic screening of flavanone derivatives was performed to identify compounds capable of dual inhibition of HIF-1α and DLL4. Among 16 natural compounds evaluated, isoxanthohumol (IXN), a prenylated flavanone, emerged as the most potent, suppressing both hypoxia-induced HIF-1α accumulation in tumor cells and VEGF-induced DLL4 expression in endothelial cells. IXN markedly inhibited endothelial proliferation, migration, and tube formation in vitro. In a Lewis lung carcinoma (LLC) mouse syngeneic model, IXN monotherapy reduced tumor growth and vessel density. Notably, combination treatment with IXN and anti-PD-1 immunotherapy produced greater anti-tumor effects than either monotherapy. This combination enhanced cytotoxic T cell infiltration into the tumor core, increased granzyme B expression, and induced widespread tumor cell apoptosis, consistent with improved vascular normalization. These findings identify IXN as a promising dual-targeting agent that inhibits both HIF-1α and DLL4 and demonstrate its potential to enhance immune checkpoint blockade. Simultaneous targeting of hypoxia-driven and VEGF-DLL4-mediated angiogenic pathways represents a compelling therapeutic strategy to overcome the limitations of current anti-angiogenic and immunotherapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoxia-Inducible Factor 1, alpha SubunitXanthonesImmune Checkpoint InhibitorsCarcinoma, Lewis LungCalcium-Binding ProteinsAdaptor Proteins, Signal TransducingAnimalsHumansMiceNeovascularization, PathologicCell ProliferationVascular Endothelial Growth Factor ACell Line, TumorMice, Inbred C57BL

Stichwörter der Autor:innen

DLL4-NOTCH1 signaling pathwayHIF-1αflavanoneimmune checkpoint inhibitorsvascular normalization

Substanzen

Hypoxia-Inducible Factor 1, alpha SubunitXanthonesisoxanthohumolImmune Checkpoint InhibitorsCalcium-Binding ProteinsVascular Endothelial Growth Factor AAdaptor Proteins, Signal TransducingDLL4 protein, humanDLL4 protein, mouse

Autor:innen und Institutionen

  • Vessel-Organ Interaction Research Center, VOICE (MRC), College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.
  • BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Republic of Korea.

ORCID-Profile: Jihye You, So Hee Bae, Jong Hwa Jung, Jeong Ah Kim, You Mie Lee

Förderung

  • Government of the Republic of Korea
  • National Research Foundation of Korea

Zitieren

APA

Kim, D., You, J., Bae, S. H., Jeong, J. H., Jung, J. H., Kim, J. A., & Lee, Y. M. (2026). Dual Targeting of HIF-1α and DLL4 by Isoxanthohumol Potentiates Immune Checkpoint Blockade. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031576

Vancouver

Kim D, You J, Bae SH, Jeong JH, Jung JH, Kim JA, et al. Dual Targeting of HIF-1α and DLL4 by Isoxanthohumol Potentiates Immune Checkpoint Blockade. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031576

BibTeX
@article{Kim2026,
  author = {Kim, Doyoung and You, Jihye and Bae, So Hee and Jeong, Ji-Hak and Jung, Jong Hwa and Kim, Jeong Ah and Lee, You Mie},
  title = {Dual Targeting of HIF-1α and DLL4 by Isoxanthohumol Potentiates Immune Checkpoint Blockade},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031576}
}
Kostenlos starten →